247 related articles for article (PubMed ID: 31062404)
1. Lichen planus pemphigoides developing from patient with non-small-cell lung cancer treated with nivolumab.
Sato Y; Fujimura T; Mizuashi M; Aiba S
J Dermatol; 2019 Oct; 46(10):e374-e375. PubMed ID: 31062404
[No Abstract] [Full Text] [Related]
2. Atezolizumab-induced lichen planus pemphigoides in a patient with metastatic non-small-cell lung cancer.
Senoo H; Kawakami Y; Yokoyama E; Yamasaki O; Morizane S
J Dermatol; 2020 Apr; 47(4):e121-e122. PubMed ID: 31984550
[No Abstract] [Full Text] [Related]
3. Detection of anti-BP180 NC16A autoantibodies after the onset of dipeptidyl peptidase-IV inhibitor-associated bullous pemphigoid: a report of three patients.
Mai Y; Nishie W; Izumi K; Yoshimoto N; Morita Y; Watanabe M; Toyonaga E; Ujiie H; Iwata H; Fujita Y; Nomura T; Sato-Matsumura KC; Shimizu S; Shimizu H
Br J Dermatol; 2018 Sep; 179(3):790-791. PubMed ID: 29624639
[No Abstract] [Full Text] [Related]
4. Nivolumab-induced lichen planus pemphigoides.
Strickley JD; Vence LM; Burton SK; Callen JP
Cutis; 2019 Apr; 103(4):224-226. PubMed ID: 31116807
[TBL] [Abstract][Full Text] [Related]
5. Detection of IgG antibodies to BP180 NC16a and C-terminal domains and LAD-1 in nivolumab-associated bullous pemphigoid.
Matsui Y; Makino T; Ishii N; Hashimoto T; Shimizu T
Eur J Dermatol; 2019 Oct; 29(5):554-555. PubMed ID: 31570332
[No Abstract] [Full Text] [Related]
6. Bullous pemphigoid induced by pembrolizumab in a patient with advanced melanoma expressing collagen XVII.
Wada N; Uchi H; Furue M
J Dermatol; 2017 Oct; 44(10):e240-e241. PubMed ID: 28677843
[No Abstract] [Full Text] [Related]
7. Lichen Planus Pemphigoides: From Lichenoid Inflammation to Autoantibody-Mediated Blistering.
Hübner F; Langan EA; Recke A
Front Immunol; 2019; 10():1389. PubMed ID: 31312198
[TBL] [Abstract][Full Text] [Related]
8. More Severe Erosive Phenotype Despite Lower Circulating Autoantibody Levels in Dipeptidyl Peptidase-4 Inhibitor (DPP4i)-Associated Bullous Pemphigoid: A Retrospective Cohort Study.
Ständer S; Schmidt E; Zillikens D; Ludwig RJ; Kridin K
Am J Clin Dermatol; 2021 Jan; 22(1):117-127. PubMed ID: 33026629
[TBL] [Abstract][Full Text] [Related]
9. Dipeptidyl peptidase-4 inhibitor-related bullous pemphigoid showing positive autoantibody responses to multiple epitopes.
Kitao R; Fukumoto T; Hashimoto T; Izumi K; Jimbo H; Takemori C; Nishigori C
J Dermatol Sci; 2021 Sep; 103(3):190-192. PubMed ID: 34489165
[No Abstract] [Full Text] [Related]
10. Bullous lichen planus accompanied by elevation of serum anti-BP180 autoantibody: A possible transitional mechanism to lichen planus pemphigoides.
Fujii M; Takahashi I; Honma M; Ishida-Yamamoto A
J Dermatol; 2017 Jun; 44(6):e124-e125. PubMed ID: 28105695
[No Abstract] [Full Text] [Related]
11. Decrease in eosinophils infiltrating into the skin of patients with dipeptidyl peptidase-4 inhibitor-related bullous pemphigoid.
Chijiwa C; Takeoka S; Kamata M; Tateishi M; Fukaya S; Hayashi K; Fukuyasu A; Tanaka T; Ishikawa T; Ohnishi T; Watanabe S; Tada Y
J Dermatol; 2018 May; 45(5):596-599. PubMed ID: 29411416
[TBL] [Abstract][Full Text] [Related]
12. Detection and characterization of IgG, IgE, and IgA autoantibodies in patients with bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitors.
Fania L; Salemme A; Provini A; Pagnanelli G; Collina MC; Abeni D; Didona B; Di Zenzo G; Mazzanti C
J Am Acad Dermatol; 2018 Mar; 78(3):592-595. PubMed ID: 28987492
[No Abstract] [Full Text] [Related]
13. IgG autoantibodies from a lichen planus pemphigoides patient recognize the NC16A domain of the bullous pemphigoid antigen 180.
Skaria M; Salomon D; Jaunin F; Friedli A; Saurat JH; Borradori L
Dermatology; 1999; 199(3):253-5. PubMed ID: 10592407
[TBL] [Abstract][Full Text] [Related]
14. Atypical subacute cutaneous lupus erythematosus presenting as lichen planus pemphigoides with autoantibodies to C-terminus of BP180, desmoglein 1 and SS-A/Ro antigen.
Inoue Y; Adachi A; Ueno M; Fukumoto T; Nishitani N; Fujiwara N; Yamada Y; Ohyama B; Tsuruta D; Hashimoto T
J Dermatol; 2012 Nov; 39(11):960-2. PubMed ID: 22413755
[No Abstract] [Full Text] [Related]
15. Rituximab Treatment of Nivolumab-Induced Bullous Pemphigoid.
Sowerby L; Dewan AK; Granter S; Gandhi L; LeBoeuf NR
JAMA Dermatol; 2017 Jun; 153(6):603-605. PubMed ID: 28355425
[No Abstract] [Full Text] [Related]
16. Lichen planus pemphigoides: detection of anti-BP 180 antibodies by ELISA and immunoblotting tests.
Barnadas MA; Roé E; Dalmau J; Alomar A; Martínez L; Gelpí C
J Eur Acad Dermatol Venereol; 2010 Nov; 24(11):1360-1. PubMed ID: 20337815
[No Abstract] [Full Text] [Related]
17. Βullous pemphigoid in patients with DPP-4 inhibitors at the onset of disease: does this differ from common bullous pemphigoid?
Patsatsi A; Kyriakou A; Meltzanidou P; Trigoni A; Lamprou F; Kokolios M; Giannakou A
Eur J Dermatol; 2018 Oct; 28(5):711-713. PubMed ID: 30325322
[No Abstract] [Full Text] [Related]
18. Regulatory T cell subsets in bullous pemphigoid and dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid.
Muramatsu K; Zheng M; Yoshimoto N; Ito T; Ujiie I; Iwata H; Shimizu H; Ujiie H
J Dermatol Sci; 2020 Oct; 100(1):23-30. PubMed ID: 32843228
[TBL] [Abstract][Full Text] [Related]
19. Epitope-spreading phenomena in dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid.
García-Díez I; España A; Iranzo P
Br J Dermatol; 2019 May; 180(5):1267-1268. PubMed ID: 30675718
[No Abstract] [Full Text] [Related]
20. Lichen Planus Pemphigoides Mimicking Toxic Epidermal Necrolysis.
Ondhia C; Kaur C; Mee J; Natkunarajah J; Singh M
Am J Dermatopathol; 2019 Nov; 41(11):e144-e147. PubMed ID: 31145106
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
